Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 129

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 129
---
 events
or other undesirable side effects caused by our product candidates could cause us, IRBs or regulatory authorities to interrupt, delay
or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval or certification by
the FDA or other comparable foreign regulatory authorities.

| 52 |

During the conduct
of clinical studies, patients may report changes in their health, including illness, injury, or discomfort, to their study doctor. Often,
it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we
test our product candidates in larger, longer and more extensive clinical studies, or as use of these product candidates becomes more
widespread if they receive regulatory approval or certification, illnesses, injuries, discomfort and other adverse events that were observed
in previous trials, as well as conditions that did not occur or were undetected in previous trials, will be reported by patients. Many
times, side effects are only detectable after investigational products are tested in large-scale clinical studies or, in some cases, after
they are made available to patients on a commercial scale following approval or certification.

If any serious
adverse events occur, clinical studies or commercial distribution of any product candidates or products we develop could be suspended
or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the
ability of enrolled patients to complete trials or result in potential liability claims. Regulatory authorities could order us to cease
further development of, deny approval of, or require us to cease selling products for any or all targeted indications. If we are required
to delay, suspend or terminate any clinical study or commercialization efforts, the commercial prospects of such product candidates or
products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed
or eliminated. Additionally, if one or more of our product candidates receives marketing approval or certification and we or others later
identify undesirable side effects or adverse events caused by such products which could lead to a number of potentially significant negative
consequences, including but not limited to:

| ● | we may encounter restrictions on the marketing or manufacturing of the product, complete withdrawal of 
 the product from the market or product recalls;                                                        |

| ● | regulatory authorities may suspend, limit or withdraw approvals or certifications of such product, or 
 seek an injunction against its manufacture or distribution;                                           |

| ● | regulatory authorities may require additional warnings on